Endo International plc is a global pharmaceutical company that develops, manufactures, and distributes a range of branded and generic pharmaceuticals, medical devices, and consumer health products. The company's products are primarily used in the fields of pain management, urology, endocrinology, and oncology.
Endo operates through four segments: Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables, and International Pharmaceuticals. The Branded Pharmaceuticals segment focuses on the development, manufacturing, marketing, and sale of branded prescription products. The Generic Pharmaceuticals segment develops, manufactures, and distributes generic prescription products. The Sterile Injectables segment develops and manufactures generic sterile injectable products. The International Pharmaceuticals segment includes branded and generic products in international markets.
Endo's product portfolio includes a broad range of pharmaceuticals, medical devices, and consumer health products. Some of its notable branded products include Lidoderm, Voltaren Gel, Xiaflex, Aveed, Supprelin LA, and Vantas. The company also manufactures and distributes a range of generic pharmaceuticals, including opioids and other pain management drugs.
In addition to its pharmaceuticals business, Endo also operates Par Pharmaceutical, a leading generics manufacturer in the U.S., and Paladin Labs, a specialty pharmaceuticals company with operations in Canada and select international markets.
Endo is committed to sustainability and corporate responsibility. The company has set goals to reduce its environmental impact, increase access to healthcare, and enhance diversity and inclusion within its workforce.
Headquartered in Dublin, Ireland, Endo has operations in North America, Europe, and Asia. The company is listed on the Nasdaq stock exchange under the ticker symbol ENDP.
|
